text:
As everyone knows, Steve Jobs did not graduate from Reed College. (He may, in fact, be one of the most famous "non-graduates" in modern history). Nonetheless, his experience at Reed left a profound impression on him, as he reiterated on many occasions.
This week, the biopic Jobs, starring Ashton Kutcher as Steve Jobs (and James Woods as Dean Jack Dudman '42), is being released to theaters around the world. In light of the enduring fascination with all things Steve, we decided to pull together some information about his time on campus. Visit our page on Steve Jobs at Reed for more details.
Continue reading Steve Jobs and Reed
Visionary. Iconoclast. Rebel. Even though Steve Jobs was officially enrolled for just one semester, he was the quintessential Reedie.
It is far beyond the scope of this obituary to trace his protean career at Apple or assess his accomplishments and failures (and there were many of each). Classmates hardly need to be reminded of how he transformed the personal computer, the cell phone, and the music player, and how those devices in turn revolutionized a dozen industries.
But it is worth taking a closer look at Steve's time on campus, because Reed was a much deeper part of him than one might think from his official transcript. In his crystalline intensity, his obsession with big ideas, his hunger for perfection, he personified the classic Reed archetype.
Continue reading Prodigal Son
In the winter of 1996–97, a band of Reed students including Justin Campbell '99 and Colin McCluney '99 took the Doyle Owl on a road trip to California. On a whim, they stopped by Steve Jobs' house in Palo Alto and rang the bell. They were floored when Steve emerged, admired the Owl, talked about Reed, and posed for this photo in Justin's parents' minivan. "He was really nice about it," Justin says.
Continue reading Steve and the Owl
Prof. Jack Dudman '42 played many roles at Reed—often simultaneously. Student leader, proud graduate, inspiring teacher, patient mentor. But he is probably best remembered as dean of students, an office he held from 1963 to 1983—during which time he helped hundreds of students through some of the most difficult times of their lives.
John Almon Dudman was born in Iowa in 1920 and majored in mathematics at Reed, where he made a deep impression on Prof. Robert Rosenbaum [math 1939–53]. "Jack was the best of the group," Rosenbaum wrote later. "Not just in seriousness and diligence, although he clearly held his own in these qualities—but in the imagination that he brought to his study, and in the evident pleasure that he took from beginning to see the roles that mathematics plays in human culture."
Dudman was elected student body president and became an active student advocate. During that time, two male students were involved in a homosexual relationship which somehow became public; college administrators were determined to put an end to it. Dudman argued that the students' relationship was a private matter and that the college had no business meddling in their affairs. Sadly, his arguments fell on deaf ears and the students were expelled.
Continue reading The Dudman Files
(From Steve Jobs' Convocation speech on August 27, 1991, at which he was given the Vollum Award for Distinguished Accomplishment in Science and Technology.)
Thank you very much for this. It means a lot to me. I'm a peculiar Reed alumnus, as many of you know. I never graduated from Reed—although that doesn't make that unusual, I suppose.
But maybe more unusual: I ran out of money after one semester here at Reed, so I dropped out, but then I dropped in for another year-and-a-half. So, I was actually here by choice. This is somewhat more unusual. And I had some experiences here that I'm sure many of you will have as freshmen and throughout your years here, that have stayed with me my whole life. I was thinking of some of them to recount to you.
Continue reading Staying Hungry
Reedies have known for some time that Comrades of the Quest is a signal achievement. Since its publication last summer, the magisterial oral history of Reed, edited by John Sheehy '82, has been devoured by Reedies on campus and elsewhere (check out these tidbits that were excerpted in Reed magazine). The book quickly became an invaluable tool for alumni to understand their school and their role in its history. Lately, however, Comrades and the Oral History Project—which produced the enormous treasure trove of interviews which are the basis for the book—have received recognition in the wider world as extraordinary works of scholarship.
The Oral History Association has just named the Reed College Oral History Project as the recipient of its prestigious Elizabeth Mason Large Project Award, given for outstanding works of oral history. The awards committee found that the project had been completed at "consistently high standards of professionalism, ethics, and scholarly rigor," and that it made "important contributions to the social and cultural history of education."
Continue reading Reed's Oral History Project Wins Honors
A celebration of the life of longstanding Reed trustee Ted Reich '51 will be held at the Portland Yacht Club, 2–5 p.m., on Thursday, August 22, 2013.
Classic car enthusiast, sailor, mountaineer, investor, and philanthropist, Ted was one of the world's foremost authorities on Rolls-Royce and Bentley motorcars. His fascination with automobiles began in early childhood. His father, a surgeon in Cleveland, Ohio, taught Ted to appreciate the design and details of fine motorcars, and Ted was enthralled when his cousin from England arrived at the Reich home in a Bentley. "By the time I was four, I could tell a Duesenberg from a Cadillac."
Ted came to Portland to attend Reed, where he earned a BA in psychology. "I viewed my years at Reed as positive in virtually all respects," he said later. A competitive athlete in high school, Ted loved mountain climbing and skiing in the Pacific Northwest. He hiked to the summits of the Cascade Range, and climbed Mount Hood seven times. On his twenty-first birthday, he climbed the Matterhorn in Switzerland. At Reed, he joined the Boar's Head Ensemble, and faithfully sang at the annual holiday party for 65 years.
Continue reading Memorial for Ted Reich '51 set for Aug. 22
The 2014 edition of Princeton Review's The Best 378 Colleges reveals a Reed that is both familiar to Reedies and one that exists somewhere on a plane between Reedlore and reality.
Reed was #1 in the category of "Best Classroom Experience," #2 in "Professors with the Highest Marks," #4 in "Students Who Study the Most," and #19 in the categories of "Great Financial Aid" and "Most Accessible Professors."
Kim Durkin '13 commented on the outmoded stereotype where Reed landed at #4 in the category, "Birkenstock-Wearing, Tree-Hugging, Clove-Smoking Vegetarians." "Is this 1980? There are plenty of vegetarians, and we do love our trees (the college has a website dedicated to them), but that's not the picture I get when I think of Reed."
Continue reading Reed College Ranked #1 in Best Classroom Experience
Reed Switchboard, the networking site created to share Reed love, has been given a boost by Wieden & Kennedy as part of the ad firm's Portland Incubator Experiment (PIE). Switchboard is the networking brainchild of Mara Zepeda '02 and Sean Lerner '10. They created the website so current Reedies and alumni could share their work experiences, offer assistance, post jobs, and give community members a leg up in a post-recession and increasingly competitive job market.
PIE had an ultra-competitive selection process, with only seven tech start-ups picked out of over 400 applicants. Switchboard, a Reedie endeavor, manned by Reedies, and beta tested on Reedies, was one of the lucky seven. Each startupreceives $20,000 in seed money, office space at Wieden & Kennedy, and three months of hands on mentorship from past PIE winners and other successful technological ventures.
Mara and Sean are hoping to use the money and expertise they gain through PIE to open up Switchboard to other college communities, offering the same basic format that connects Reedies with Reedies, but instead connecting Clarkies with Clarkies, and so on.
Continue reading Reed Switchboard Selected from 400 Applicants for $20K Slice of PIE
This summer finds Reed students interning at the Paris Review, studying the art of Japanese woodblock printing in Kyoto, farming organically in the Provence, and interning at a law firm.
Learning for its own sake is a trope frequently invoked to describe a liberal arts education. Conventional wisdom, however, holds that employers flock to those college graduates with quantifiable workplace skills. Increasingly a summer internship serves as the bridge for exhibiting skills that will translate to success in the job market.
Reed's office of career services works with students to guide them in career development, hone their interviewing skills, advise on job applications, and help them access a community of partners that includes parents and alumni. One key initiative is helping students identify and secure summer internships.
Continue reading The Job Gap
Deep in a forgotten corner of the Gray Campus Center basement, down the hall from the comic book library, Reed's band practice room (BPR) is anything but glamorous. But for many Reedies it is a hallowed space, a place that (between 5 p.m. and 7 a.m. on weekdays, all day weekends) can incubate their energy and talent. For the last three years one group of Reedies in particular have made the BPR home. They call themselves Hausu, and this summer all their hard work is finally paying off.
Hausu is composed of Carl Hedman '13, Benjamin Friars-Funkhouser '14, Alexander Maguire '14, and Santiago Leyba '14. They are rockers in the vein of 1990s indie bands like Sebadoh and Sonic Youth, and their debut album, Total, is full of interlocking guitar pieces and post-punk snarl. Total was released by Hardly Art Records on June 25. So far it has met with nearly unanimous acclaim. The Portland Mercury called "one of the finest debut records in recent memory," while the website Allmusic called the album "infectious," and wrote that its single, "Leaning Mess," felt like a "distant classic." The album's release was timed to coincide with Hausu's six-week, cross-country tour, which took them from Portland to New York City and back.
Hausu recorded Total over winter break, but the band had been honing the songs on the album since their first jam three years ago. It wasn't always easy for the band members to align their schedules: last year Carl wrote his thesis in economics, while Ben, Alex, and Santi all took the junior qual (in art history, anthropology, and studio art, respectively). "it was difficult to make time to play the music," Carl said, "but it was an important catharsis for us to deal with academic stress."
Continue reading Reed Band's Debut Album Wins Acclaim
Fanning themselves with their programs in a standing-room-only Eliot Hall chapel, the audience was transported straight to the barrios of Buenos Aires as the violins, basses, bandoneones and piano plunged into a sultry tango beat.
The nine players kicked off the grand finale of the Reed College Tango Music Institute, held June 23-30, 2013. For the next two hours, 53 musicians of varying experience and combinations showcased what they'd learned that week under the tutelage of four of the world's preeminent tango musicians. Bassist Pablo Aslan, pianist Octavio Brunetti, and bandoneonist Julian Hasse, all Argentine-born, and U.S. violinist Nick Danielson capped the evening with a couple of virtuosic romps that lifted the applauding crowd to its feet, stomping for an encore. Many in the crowd refused to sit back down until they'd tangoed well past midnight at the milonga that followed in Student Union, led by Alex Krebs '99.
Continue reading Tangled up in Tango
This summer Dominic Finocchiaro '11 will present his new play, complex, at Portland's JAW: A Playwrights Festival. He was one of four playwrights—chosen from more than 200 submissions worldwide—who will collaborate with theatre professionals from across the country before presenting their works in staged, public readings.
Sponsored by Portland Center Stage, the two-week JAW (short for Just Add Water) festival, spotlights new works selected through a blind submission process. complex will be presented at 4 p.m. on Friday, July 26, at the Armory. The story takes place a big city apartment complex where residents are dying in strange and gruesome ways. One tenant sets out to stop the bloodshed and mayhem.
Continue reading JAWing with Dominic
Humankind's view of the cosmos, however magnificent, is fundamentally static. Astrophysicists know that distant astronomical objects (stars, nebulae, galaxies) are in constant motion, but this is invisible to human eyes because it takes place on a timescale which is unimaginably vast. In fact, except for the moon, the planets, and the occasional comet, the night sky has looked essentially the same for the entire history of human civilization.
Recently astrophysicists have used computers to speed things up. For my thesis with Johnny Powell [physics 1987–], I wrote a computer program to simulate the evolution of a typical spiral galaxy. The central premise is that by calculating the gravitational forces acting on a relatively small number of stars, we can simulate the evolution of a real galaxy, which consists of hundreds of billions of stars.
Continue reading How a Galaxy Evolves
Fresh bread, sweet honey, and a crisp wine to wash to all down. It's not heaven, but it may be the next best thing: Gastronomy Northwest, the annual festival of food and drink produced by and for alumni, was held on Saturday afternoon of Reunions '13: Reedfayre.
Making a piquant comeback from last year were David Autrey '89 and his partner Amy Wesselman '91 of the Westrey Wine Company, who served a delicate 2012 pinot gris and a refreshing 2010 pinot noir (you may have heard of their rising-star sons?). Also returning was the Clear Creek Distillery, operated by master distiller Steve McCarthy '66 and his wife, artist Lucinda Parker McCarthy '66. The Portland distillery employs mostly Reedies and specializes in brandies and liqueurs created from the fruit grown in the family's orchards at the foot of Mount Hood. Their summery loganberry liqueur accented the natural tartness of the berry while perfectly satisfying the sweet tooth.
Continue reading Savoring the Taste of Reed
Retiring profs, including (left) Pat McDougal [chemistry] and (next to him) Ellen Stauder [English] were honored at Fanfayre '13. Photo by Leah Nash
Like Janus, the two-faced Roman god of beginnings and transitions, Reunions '13: Fanfayre looked back to the past and forward to the college's future in its recognition of distinguished alumni and faculty.
The keynote speaker was Eduardo Ochoa '73, former Assistant Secretary for Postsecondary Education and current president of California State University, Monterey Bay. Eduardo, who also holds degrees in economics and nuclear engineering, analyzed the strengths, weaknesses, opportunities, and threats facing liberal arts colleges. He emphasized first the rapid pace of social change and the pressing need for a better-educated workforce in every sector of the economy. However, the rising cost of tuition poses a huge threat. "Only two percent of the population attend liberal art institutions," he remarked. Liberal art colleges with a strong reputation and sound financial position (such as Reed) can still draw the best students, which represents an opportunity, especially since these students can become future leaders. "Reed has to focus on their leadership development because God knows we need it, after what I've seen in Washington," he said.
Continue reading Fanfayre '13 Looks Back, Looks Ahead
One of the highlights of Reunions '13: Reedfayre was Alumni College, a multi-disciplinary series of conversations and outings for Reedies of all ages. Aesthetics was the theme of this year's Alumni College #2 (which took place after Reedfayre), and school opened bright and early on Monday morning with a conference on Immanuel Kant's Critique of Judgment (1790), led by Jan Mieszkowski [German 1997–].
Mieszkowski started the conference with a question that is central to Kantian aesthetics: what does it mean to say that an object is beautiful? Naturally the gathered Reedies—including Harry Travis '69, Lowell Weitkamp '58, Carole Maxwell Stuart '63, Monica Mayper '73, and Chilton Gregory '60—turned to the objects at hand: the stools they had built by hand under the tutelage of master woodworker Gary Rogowski '72 the previous day. The group agreed that Chilton's stool was particularly attractive, but Kant's claim that a true aesthetic judgment was devoid of all interest provoked skepticism in some of the conference participants. Evolutionary biology, the Russian painter Wassily Kandinsky, and rose gardening were topics in the fiery debate on beauty and genius that followed.
In the afternoon the debate over aesthetics carried over to the kitchen, where the James-Beard-award-winning chef Diane Morgan '77 took the same group of scholars through a series of recipes. Other sessions included:
Continue reading Kant, Reed, and the Aesthetics of Stools
Dozens of alumni packed themselves into a little classroom in Eliot Hall today for a chance to hear Professor Emeritus Marvin Levich [philosophy 1953–1994] discussing that most perplexing of subjects, the sixties.
The dapper suits and plume of cigarette smoke that once signaled his presence were long gone, replaced by blue jeans, sneakers, and a flat cap. He walks slowly down the hallway and his voice no longer booms—in fact, it sounds more like the rasp of sandpaper. But his eyes—and his ideas—have lost none of their intensity.
Continue reading Reed and the Sixties
The effect of nitrogen dioxide on aerosol formation might not sound like a particularly creative field of study—unless you study chemistry at Reed.
Chem major Danielle Draper '13 just won the coveted Class of '21 Award, recognizing exceptional creativity, initiative, and spontaneity, for her thesis, which looked at how nitrogen dioxide (NO2) emitted by vehicles affects the formation of aerosols, or tiny particles, in forests. It turns out that trees naturally emit gasses—like those responsible for the scent of spruce needles—that turn into aerosols in the atmosphere. Danielle wanted to know how that process was affected by manmade emissions--in other words, how humans are changing the "natural" flow of a forest. In particular, she investigated this reaction as it occured at night, under the cover of darkness.
To conduct her experiments, Danielle had to construct an atmospheric chamber, build a special computer model to study chemical kinetics, and analyze reams of data. Her findings were intriguing. While most tree emissions (e.g. the spruce-scent particles) react with NO2 to create more particles in the atmosphere than they would have alone, alpha-pinene, an emission largely found in pine trees, actually produced fewer particles when combined with NO2.
Continue reading Chem Major Nabs Class of '21 Award
Saturday night at Reunions '13: Reedfayre, June 12-16, doesn't begin with the fireworks. This year, it starts with Tezeta Band, Portland's premier Ethiopian-style rock band. Tezeta Band is a sort of reunion in itself: the band is composed of members of the Five Fingers of Funk, the hip-hop funk fusion band that rocked Portland in the 1990s.
Formed in 1992, with a career that spanned nearly 10 years, Five Fingers was the Pacific Northwest's premier hip-hop experience, opening for the likes of De La Soul, The Roots, and Run DMC. Five Fingers wound down in the early oughts, with frontman-rapper Pete Miser leaving Portland for Brooklyn. The rest of the band stayed in the Rose City, however, and, after a few years pursuing their own projects, came back together in 2006 to explore new sonic territory: Ethiopia. For the last seven years the band has jammed on the unique fusion of jazz, rock, soul, and traditional African that defined Ethiopian music during its golden era of the 1960s and '70s (captured in the wonderful album series Éthiopiques). Tezeta will be bringing all their influences on Saturday evening, so whether you're a hip-hop head or a funk connoisseur, come on down to the SU and be prepared to boogie.
Continue reading Getting Funky at Reunions
< Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Next >


text:
Posts Tagged: outdated gadgets
Oct 21, 20112 Comments
TNI Trend List: Siri Engine Optimization, Google Hiding Referral Data in AnalyticsThe Net Impact Trend List is a semi-weekly look at relevant news, blogs, trending searches, and our client successes. For those interested in social media, SEO, and web development, trend on. Worth a Look Tech gadgets are always a popular topic of conversation this time of year as many speculate which tech toys will be...

subset: commoncrawl


text:
Sounds like a variant on your typical lone wolf nut job to me.
If these books are indeed Great American Novels—a distinct category, a variant of excellence—they are generally big in every way.
Still, the resounding response globally has been some variant of "What the hell is going on?"
These were the expensive Austrian variant: the sleek silver-and-blue cans that cost roughly $1.50 each.
Everyone made a big deal out of the fact that he used "conservative," or a variant thereof, two dozen times in the speech.
The character's a variant on any of those that have been discovered so far.
It may also represent merry, in its variant form murie, which is Mid.
variant spellings were made consistent when a predominant usage was found.
variant spellings and unusual punctuation have been retained.
And H 18, as also a variant to B 20, says it was a rune-slumber that came over him.
variant var·i·ant (vâr'ē-ənt, vār'-)
Having or exhibiting variation; differing.
Tending or liable to vary; variable.
Deviating from a standard, usually by only a slight difference.


text:
Zooey Dechanel is a very beautiful girl and a successful actress and singer. She seems to be very confident but she says that she wasn't always that way.
In fact, as a child Zooey was bullied. She says that her sense of humor allowed her to make it through her early teen years and helped her develop a thick skin that still comes in handy for her to this day.
"Seventh grade was the ultimate low rock bottom—someone spitting in your face while you are on your way to your locker. Having to fight your way through those years makes you ready for the future. I can snap back, I can make fun of myself before they do—I can do all of it. There's no way I can ever be as sensitive as I used to be, and it's sad to lose any sensitivity because it generally makes people very good at art," she said.
"I've seen a lot of people turn—sometimes it unlocks who they really are. They turn into celebrities are who are separate from themselves. That's OK, but I just don't want to be like that." She added, "I have to be normal. My mother wouldn't let me be any other way."
She also said that her experience with bullying has made her a more down to earth person and that fame has not changed her as a person. When it comes to brand names, labels and money, Zooey said that she doesn't have to spend a lot of money on something to enjoy it. She also said that she is bothered by people who feel the opposite.
Hooray!!!! "@InStyle: And our Aug cover girl is… @ZooeyDeschanel! Get your 1st peek:
http://t.co/NQuILfylyC pic.twitter.com/pdHHwerdO0"
— zooey deschanel (@ZooeyDeschanel) July 6, 2014
"I remember I was wearing a cute jacket, and I saw this well-known actress—who will remain nameless—with her stylist. They said, 'Oh my god, that's so cute. Where did you get it?' I told them, and it was not a fancy brand, and they were like, 'Oh.' I just thought, 'Do you not like it anymore because of the brand?' That's so dumb," Deschanel said. "And you have just made yourself into a cartoon villain."
Zooey knows a little about fashion, she did after all recently work with Tommy Hilfiger to release a new line of clothing.
What do you think of Zooey Deschanel and have you seen her new clothing line?
Image via Wikimedia Commons


text:
TOP STORY >>Drought, heat start to ease, but watch out
Leader staff writer
Temperatures are dropping into the low 90s for the weekend and a sprinkling of rain has misted most of the state, but the reality of heat-related deaths remains.
The state Health Department has confirmed eight heat-related deaths so far this summer, most occurring because of Augusts 12 days of 100-plus degrees.
According to John Senner, branch chief for the Center for Health Statistics, Arkansas averages 10 heat-related deaths a year.
The heat wave topped off Aug. 12 at 106 degrees, and most recently hit 100 degrees Monday. The 106-degree high of Aug. 12 was the hottest temperature central Arkansas has seen in seven years. August ended with 28 days of highs of 95 degrees or greater and a high temperature average about six degrees above the norm.
The heat has been exacerbated by the lack of rain. Most of the central Arkansas went almost the entire month without more than a sprinkle of rain, forcing all central Arkansas counties to issue burn bans. In all, 58 of the states 75 counties have issued burn bans.
Most of the state is suffering moderate to extreme drought conditions. Pulaski, Lonoke and White counties are in the severe category according to the National Weather Service.
Pulaski Countys rain totals for August were more than two inches below the average, and the area is more than six inches off the norm for the year.
Officials at the Centers for Disease Control and Prevention said excessive heat exposure caused more than 8,000 deaths in the United States over the past 25 years.
While elderly, people with health problems and very young children are the most vulnerable, heat can affect anyoneeven strong, healthy athletes can be stricken, officials said.
Ann Wright, with the Arkansas Health Department, explained that several factors affect the bodys ability to cool itself during extremely hot weather.
When the humidity is high, sweat will not evaporate as quickly, preventing the body from releasing heat quickly.
Other conditions related to risk include age, obesity, fever, dehydration, heart diseases, mental illness, poor circulation, sunburn and drug use, including alcohol.
Our bodies are cooled primarily by losing heat through the skin by perspiration and evaporation, Wright said. Problems occur when we are unable to shed excess heat. When our heat gain exceeds the amount we can get rid of, our temperature begins to rise and a heat-related illness may develop, she said.
Heat illness or conditions include rashes, cramps, heat exhaustion and heat stroke.
Heat exhaustion and heat stroke can be fatal.


text: I have recently removed the flatbed off of my Chev 1 ton dually and am in the process of adding a hydraulic cylinder to turn it into a flatbed dump. I was given a hydraulic cylinder that is 43" long, that fully extends to 73". It has a 4" bore and a 2" rod. It calculates to a bit over 28,000lbs of force. More then enough for the load I wil carry on this truck. I have a new pump etc. With such a long cylinder I have limited options as to how I can mount it. This system will be a "push" type similiar to the type used on dump trailers. Currently I have it mocked into position. How can I calculate the force generated by the mounting geometry I am hoping to use? Fixed end of the cylinder is 10" below the end attached to the bed, which makes the cylinder point up to start pushing up at a 13.5 degree angle. Attachement point on the bed is 30" from the pivot point the bed will pivot on. Bed is 108" long. I have tried to describe this as best I can. After looking at alot of 1 ton dumps I have tried to mimic as best I can with what I have. can anyone help me figure out if this will be adequate? Looking at the geometry on my mini excavators dipper arm there even less of an advantage on boom and dipper cylinder then I have here. I appreciate any help that can be provided.


text:
10 Daagraad Street,
Tesis Konumu
Take Jeffreys Bay off-ramp from N2. Follow town directions to Da Gama road, keep sea on left and follow road to end. Turn left at T-junction after Billabong Factory (Duine St). First left into Dageraad St, left into cul-de-sac.
Hostelworld Mobil Uygulamaları
Yeni Hostelworld mobil uygulamalarıyla hareket halindeyken rezervasyon yapın.


text:
Seattle Coffee Gear offers a selection of customer-accessible parts and tune-up kits to help keep your machine in tip-top shape! If your coffee or espresso producing apparatus is in need of a little more TLC, our tech crew offers a variety of professional tune-up and repair services.
If you're looking for internal parts and have a DIY spirit, here are some folks that can help hook you up: Encompass Parts and Espresso Parts!
Rocket Espresso R58 Control Board for - V2This control board is included in the Rocket R58 dual boiler - V2. It can be installed in Version 1 R58 espresso machines to upgrade brew and steam boiler functionality. Learn More$125.29
Out of Stock
BUNN 1.5 Gallon ThermoFresh ServerEven here at our place on Monday morning there can be a line queuing for coffee. Someone usually daydreams aloud about brewing directly into their mouth. Skip the line, and the scalded mouth, by having plenty of coffee on-hand with the BUNN 1.5 gallon ThermoFersh server. It has a visible gauge so you know when you are running low. Purchase more than one as insurance to never have to wait for a batch to brew. Learn More$299.00
Curtis ThermoPro 1.5 Gallon Thermal Server with BaseThe ThermoPro G4 Digital Coffee Brewing Systems use the Curtis ThermoPro 1.5 gallon thermal servers. These are designed to provide optimum heat retention and the stainless steel liner provides commercial durability. The base makes it easy to set up and transport as does the sturdy handles. The brew through top keeps the heat and all the flavor in. There is a separate drip tray for easy cup location and cleaning. Just over 8 inches of cup clearance allows for easy filling of anything from a short to a venti cup. Learn More$299.00
La Marzocco GS/3 Bottomless PortafilterIf you have never seen the crema that comes off of a bottomless portafilter, allow us to express just how perfect it is, both in taste and in aesthetics. La Marzocco has created this Bottomless Portafilter for its wonderfully designed GS/3 machines. Learn More
Regular Price: $118.80
Out of Stock
Saeco Xelsis Milk Carafe V1Seattle Coffee Gear carries a full line of espresso machine parts and accessories. Learn More$161.69
Out of Stock
Saeco Xelsis Exprelia Milk Carafe Assembly V3Complete milk frothing carafe for the Saeco Xelsis. This is the Version 3 carafe which only fits machines with a serial number of 9009SA40298917 or greater. Learn More$153.09
Out of Stock
Rocket Giotto Evoluzione Drip TrayThe Rocket Giotto Evoluzione Drip Tray works to contain the espresso mess all in one place. It is an easy replacement process if yours has gone missing or was twisted under the tire of a monster truck at last night's rally. The Professional model is a "plumb-in" only and the Evoluzione is a versatile plumbed or tank model. This replacement for the drip tray fits either model. Learn More$123.59
Out of Stock
Saeco Milk Island for Talea Models - .8 LiterThe Saeco Milk Island container is a unique Saeco development for Talea models only. Whether you prefer lattes, cappuccinos, macchiatos, or any other specialty, the preparation of creamy foam takes just a matter of seconds. Learn More$139.00
Baratza Esatto Weight Operation PanelDo you have in your possession a Maestro Plus, Virtuoso or Preciso? Well maybe it's time to jazz up these grinders with the Baratza Esatto, an accessory that gives your grinder the ability to grind precise dosages of coffee using real-time weight based control. Learn More$149.00
Rocket Giotto Stainless Steel Cup Warmer RailChrome out your Rocket Giotto Espresso Machine by upgrading its plastic cup rail to one made of stainless steel. This sturdy upgrade keeps your cups in place, and also looks good in the process. Learn More$116.79


text:
This property has been removed by the agent. It may be let or temporarily removed from the market
5 bedroom detached house to rentHollybush Close, Oxhey, Hertfordshire
£2,850 pcm| £658 pw fees apply
Property Description
Letting information:
|Reduced on Rightmove:
|16 May 2012 (1896 days ago)
Key features
- Stunning 5 bedroom detached family home
- Cul de sac location
- Luxury Interior
- 2 reception rooms & study
- 3 bathrooms (2 en-suite)
- Single Garage & Parking on Drive
- Available with 1 months notice
- Unfurnished
Full description
** STUNNING FAMILY HOME IN EXCELLENT LOCATION ** 5 bedroom detached, arranged over 3 floors and located on this quiet cul-de-sac minutes to Bushey Station. Beautiful landscaped garden with patio and decking areas. Available with 1 months notice, unfurnished.
Bedroom 1
3.84m x 2.77m / 12'7 x 9'1
Bedroom 2
3.28m x 3m / 10'9 x 9'10
Bedroom 3
3.20m x 2.67m / 10'6 x 8'9
Bedroom 4
3m x 2.26m / 9'10 x 7'5
Bedroom 5
5.18m x 4.27m max / 17 x 14 max
Reception 1
7.14m x 3.73m max / 23'5 x 12'3 max
Reception 2
5.87m x 3.68m / 19'3 x 12'1
Reception 3
3.20m x 2.24m / 10'6 x 7'4
5.87m x 4.32m max / 19'3 x 14'2 max
More information from this agent
To view this media, please visit the on-line version of this page at www.rightmove.co.uk/property-to-rent/property-37741565.html
Energy Performance Certificates (EPCs)
To view this media, please visit the on-line version of this page at www.rightmove.co.uk/property-to-rent/property-37741565.html
Map & Street View
View in fullscreenView in fullscreen
Street View is unavailable in this location
Disclaimer - Administration fees may apply when renting a property in England, Wales or Northern Ireland. For more details, please contact the agent.
Property reference 1309431B. The information displayed about this property comprises a property advertisement. Rightmove.co.uk makes no warranty as to the accuracy or completeness of the advertisement or any linked or associated information, and Rightmove has no control over the content. This property advertisement does not constitute property particulars. The information is provided and maintained by invisible , Sewell & Gardner - Rickmansworth - Lettings.
Please refer to our Renting Guides for further information on how to safely rent a property.
Map data ©OpenStreetMap contributors.


text:
Continued: HRSM
Mihalik earned his bachelor's degree in business with an emphasis on transportation from Syracuse University, where he also earned a pair of master's degrees, one in instructional communication, media production and administration, and one in local government administration and management. He earned his doctoral degree in corporate public relations from Temple University.
After holding tenured faculty and administrative posts at Clemson, Oklahoma State and SUNY Brockport universities, he joined Virginia Tech in 1999 as department head and professor in the Department of Hospitality and Tourism Management. Since 2006, he has served as associate dean of the graduate school, overseeing education and the development of new graduate programs and working closely with eight college deans.
Mihalik will succeed Dr. Sheryl Kline, who has been interim dean since August 2007.


text:
« back to isupplyenergy supplier page
isupplyenergy charges different rates depending on the region of the country that you live in. Please provide your postcode to view prices for this tariff as well as to compare all other tariffs in the market to see which one is the cheapest for you.
Note: any early termination fees shown may not apply after the contract has expired. Sometimes tariff data changes or becomes out of date when a tariff has been withdrawn. UKPower.co.uk cannot always guarantee the accuracy of the data displayed. Please report any errors to email@example.com.
iSupplyEnergy is a British-owned independent energy supplier based in Bournemouth. Launched in 2012, they're now one of the fastest growing energy suppliers in the UK and thousands of new customers every month trust iSupplyEnergy to look after their energy needs.
Whether it's straightforward and low pricing, an industry leading online customer portal for managing bills, or an easy switching process, iSupplyEnergy focus on simplicity, fair prices and great customer service.
Help spread the word and share this page with your friends and family on your social networks.


text:
3 peaches, divided
¾-1 cup fresh raspberries
1 tbsp. granulated sugar
1 cup plus 1 tbsp. white wine, divided
3 tbsp. peach schnapps
step 1: Show Images
Pit and thinly slice 1 peach. Add to a bowl with the raspberries, sugar, and 1 tablespoon of white wine. Stir together gently (avoid smashing the berries or bruising the fruit.) Let stand about 20 minutes.
step 2: Show Images
Peel, pit, and coarsely chop the remaining 2 peaches. Combine in a blender or food processor with the remaining 1 cup of white wine and the peach schnapps. Puree until smooth.
step 3: Show Images
Pour the peach puree mixture into popsicle molds, filling each about 2/3 of the way full. Add a few peach slices and raspberries to each mold. (This is the popsicle mold I use. I love it!) Insert popsicle sticks* and freeze until fully set, at least a few hours. Unmold and enjoy!
step 4: Show Images
*Using popsicle sticks that don't fit the mold you have? No problem. Cover the mold(s) with foil instead of the usual lid, make a very small slit where you want the popsicle stick to go, and slide the stick in. The foil will help hold it in place in lieu of the cover. See the strawberry yogurt pop post for a visual.


text:
4 Min Read
DUBLIN (Reuters) - Ireland said it was in a strong position to impose losses on bondholders of two failed lenders despite doubts the European Central Bank would permit a move that would go way beyond solutions being discussed for Greece.
The Irish government's revival of its election pledge to go after senior bondholders in Anglo Irish Bank and Irish Nationwide coincides with its 100th day in office, prompting some analysts to interpret it as a political manoeuvre.
"The Irish economy is in an entirely different situation than the economies of some of the other countries whose budgets are in trouble," Deputy Prime Minister Eamon Gilmore told national broadcaster RTE on Thursday.
"Therefore we are in a much stronger position today than we were at the beginning of this government and certainly than we were in November to negotiate with the European Central Bank."
Since Ireland agreed an 85 billion euros (74.4 billion pound) bailout with the EU and the IMF in November its borrowing costs on the secondary market have risen to record highs due to fears a possible default in fellow euro zone struggler Greece will force Dublin into a second bailout.
The ECB, which until now has been the stumbling block to going after senior bondholders, declined to comment on Dublin's renewed interest in Anglo and Irish Nationwide.
"There will have to be agreement. It is not something the country can do unilaterally," Gilmore conceded.
Some analysts said the current turmoil over Greece would likely harden the ECB's opposition.
"The ECB has made its position very clear and as volatility and tensions continue to escalate in the euro zone, any sudden shift in policy with respect to Anglo carries risk that the market perceives it as a fundamental change in general ECB policy," Dublin-based Glas Securities said in a note.
Prime Minister Enda Kenny is riding high in the polls but he needs to fortify his coalition for tough fiscal decisions in the months ahead. Political turmoil in Greece is a stark reminder that a large parliamentary majority doesn't guarantee stability.
By eying up Anglo's unsecured senior debt, the government's move deflects attention away from its failure to secure a cut in the near 6 percent rate of interest Europe is charging on its emergency loans and an ongoing dispute with France over Ireland's iconic corporate tax rate.
"With no progress made on a rate cut to the EU/IMF package and ongoing disagreement over Ireland's corporation tax, the government needs bargaining power and there is very little left to bargain with," Glas Securities said.
Finance Minister Michael Noonan's reopening of the rallying cry "burn the bondholders" late on Wednesday was applauded by local newspapers. The Irish Daily Mail headlined with "And About Time Too, Minister."
But investors took fright. The cost of insuring Irish debt against default soared to record high as five-year credit default swaps rose to 805 basis points, up 34 bps on the day.
Ireland's government has said it is entitled to go after normally ringfenced senior bondholders in nationalised Anglo Irish and Irish Nationwide because they are banks in name only.
Senior bonds in banks rank on a par with deposits but Anglo Irish and Irish Nationwide have hived off their deposits, all equity in Anglo has been wiped out and junior bondholders have already been hit.
No euro zone government has imposed losses on senior bank bonds but Dermot O'Leary, economist with Goodbody Stockbrokers, said Europe could see Anglo Irish and Irish Nationwide as a test case.
Despite ECB opposition, Europe's paymaster, Germany, would like to see private investors shoulder part of the burden of bailing out Greece.
"A 50 percent haircut on the unsecured, unguaranteed debt in Anglo and Irish Nationwide is equivalent to about eight years of the savings that would be made if the Irish interest rate was reduced to the level that Portugal is accessing funds," O'Leary said.
Editing by Carmel Crimmins/Mike Peacock


text:
Made in the USA
Welcome. This site is intended primarily for wholesale sales of socks and fine hosiery to merchants.
Business Users: Please register by going to the LOGIN page and filling out the requested information. Once your account has been validated, you will have access to all of the features of the site, including pricing information, the ability to order online, order tracking and order history. We look forward to working with you.
All Others: Please enjoy browsing through our highly regarded sock and hosiery lines as much as you wish. We hope you find the site easy to use and helpful. Your comments and suggestions about the site and our products are welcome. Please email firstname.lastname@example.com.
Standard Merchandising Co.
1125 Wright Avenue
Camden, NJ 08103-1615
Tel: (856) 964-9700


text:
by Staff Writers
Washington DC (SPX) Jan 05, 2012
Biotechnology companies researching and developing advanced biofuels can help diversify the military's energy supply and advance U.S. national and energy security objectives. The Biotechnology Industry Organization (BIO) has thanked members of the House and Senate Armed Services Committee and Sen. Patty Murray (D-Wash.) for their bipartisan support for the commercialization of advanced biofuels in the 2012 National Defense Authorization Act.
Brent Erickson, executive vice president of BIO's Industrial and Environmental Section, stated, "The advanced biofuels industry is at an inflection point and is rapidly maturing because biotech companies have made significant private investments to commercialize the technology. The Department of Defense is providing important impetus to the industry by establishing goals to acquire 50 percent of supplies from renewable sources that meet U.S. greenhouse gas emission initiatives by 2020.
"According to the DOD's Quadrennial Defense Review in 2010, access to fuel supplies in friendly countries around the world is an important force multiplier. Advanced biofuels represent the best option for meeting military needs because they increase the military's ability to operate where needed while limiting the number of combat forces needed to protect supply lines. Biorefineries can be established in strategic locations around the United States, making use of local feedstocks to produce sustainable biofuels for the military.
"The Navy, in particular, has laid out a precise timeline for decreasing its reliance on foreign oil; it has completed the necessary testing of biofuels on schedule. Companies must continue to make substantial capital investments in large-scale production facilities in order to continue to meet the Navy's timeline for competitively priced alternatives.
"Importantly, the 2012 National Defense Authorization Act asks the Defense Department to prepare a report on the authorities available for multi-year contracts for advanced biofuels. Long-term contract authority for advanced biofuel off-take agreements could help unlock private investment in the industry.
"The bill maintains Section 526 of the Energy Independence and Security Act of 2007, which also has driven private investment in the industry. The DOD has testified to Congress that the measure is not affecting their budget - in fact, the volatile price of oil has forced the DOD several times this year to request budget reprogramming - and alternative fuel industries have also testified that they can meet the requirements of this provision."
Bio Fuel Technology and Application News
Comment on this article via your Facebook, Yahoo, AOL, Hotmail login.
Saxlund expands Waste-to-Energy solution in Karlsruhe
Amal, Sweden (SPX) Jan 05, 2012
Saxlund International has won an order worth 8 million SEK for the expansion of the Waste-to-Energy solution at the City of Karlsruhe's waste water treatment plant. The order is for a turn-key expansion to a system designed and delivered by Saxlund in 2002 that will allow Karlsruhe's waste water treatment plant to increase its capacity to take care of sewage sludge from other waste water t ... read more
|The content herein, unless otherwise known to be public domain, are Copyright 1995-2012 - Space Media Network. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. Privacy Statement


text:
Grand Parade Date: Saturday, February 25, 2017
Because of growing popularity and interest, the number of entries is limited. An entry is, but is not limited to, a float, vehicle, group of individuals, or marching unit. The judges evaluate your entry based on Creativity, Craftsmanship, and Costumes. Floats should adhere to the 2017 theme Soulard Celebrates Cinema.
All applications will be considered but are NOT GUARANTEED entry into the parade.
Make sure to fully complete the application. A copy of your application information will be emailed back to you as confirmation of receipt by the Parade Chairman.


text:
Skip navigation
Oracle Community Directory
Oracle Community FAQ
Go Directly To
Oracle Technology Network Community
My Oracle Support Community
OPN Cloud Connection
Oracle Employee Community
Oracle User Group Community
Topliners Community
Java Community
OTN Speaker Bureau
Log in
Please enter a title.
You can not post a blank message. Please type your message and try again.
More discussions
Enterprise JavaBeans
All Places
Java EE (Java Enterprise Edition)
Enterprise JavaBeans
This discussion is archived
0 Replies
Latest reply
on Aug 15, 2012 6:45 AM by 714026
how to programmatically to define schema to insert from EJB2.0?
Aug 15, 2012 6:45 AM
there is user from different client site, 1 database with different schema.
however, user may only search,update,insert,and delete with the userSchema only.
System will be storing his loginName and loginPassword whenever user login to the system
im successfully build this ViewObject but not EJB, anyone got related article or example for me? thanks in advnace
as VO example (http://www.oracle.com/technetwork/developer-tools/jdev/dynamicjdbchowto-101755.html)
is that possible to do that with ejb2.0?
I have the same question
Show 0 Likes
This content has been marked as final.
Show 0 replies


text:
Following in the footsteps of Grand Theft Auto V, ArenaNet on Thursday announced that its PC MMO Guild Wars 2 will introduce a first-person camera option through an upcoming update.
First-person mode for Guild Wars 2 will allow players to see the world as if they are standing (or running or jumping) in it. There are no restrictions for where first-person can be used in the game.
Currently, Guild Wars 2 only allows players to see the world from a third-person perspective. The new first-person camera, which is entirely optional, will be available in Guild Wars 2 through an update that is scheduled to arrive on March 10.
ArenaNet has not shared any images of what first-person looks like in Guild Wars 2, but the developer promises to do just that tomorrow, February 27, during a Twitch live stream.
The March 10 Guild Wars 2 update adds more than just the new first-person camera option. Other presentation-themed tweaks include a field of view slider, a position slider, and a new collision sensitivity setting. In addition, when the update is applied, the camera will focus on a character's head, regardless of their race or size.
Guild Wars 2 was released in summer 2012 and has sold more than 3.5 million copies to date. The game's first expansion, Heart of Thorns, was announced in January.Read More


text:
|Web Site Information :.
|Site Info Whois Traceroute RBL Check
home | Graham Wardle Official WebsiteDescription: Graham Wardle Official WebsiteFor those of you who don't know who I am, my name is Graham Wardle, I am an actor, film-maker, and photographer. I am playing Ty Borden on the Canadian television show Heartland. JitZul provided this site up for me as a part of their initiative to help aspiring artists.
Keywords: blog, post, test, video, writing, photography, contact, bio, lorem, ipsum, --, ff
Tags: grahamwardle, graham, wardle, home, official, website, writing, blog, photography, follow, rss, twitter, subscribe, video, stressed, bio, contact, videos, jitzul, watch, site, read, enjoy, photos, view, updates, lorem, ipsum, test, post, submit, email, don, photographer, know, actor, maker, provided, heartland, television,
|IP Index TLD Index Domain Index Site Index
|Copyright © 2013 dawhois.com


text:
Make Money Business Opportunity Are You Tired Of Making Payments From Day To DayTuesday, May 4th, 2010
Make money business opporotunity: Are You Ready To Start Being paid for work Online
Owning a business opportunity is something that a mass of dream of. Building a successful work from home is not something to be taken lightly or jumped in to quickly without careful consideration. Monetization of your Internet work at home is the best part; it flows from traffic the way electricity flows from a river through a dam. Prosperity in small home based business opportunity is not an accident.
Tools, Instructions And Support
* There are numerous secrets you can put into place to make your financial picture added secure.
* Find a mentor or work find a team to help you learn the ropes
* Putting the team vision to work online is powerful.
To immediately get your affiliate home based business started out in the right direction, have a goal, a plan, a strategy and a system in place. Even if you are not a web-savvy tech guru, starting a website for your affiliate home based business can still be relatively easy. If you are ready to take your future into your own hands, it may be time to consider starting your own business opportunity.
Forty six (46%) percent of home-based and micro affiliate marketing business owners recently surveyed cited that making lots of money was a motivation for starting their own affiliate home based business. In most cases, starting a home business entails a small investment or start up cost. Start learning the skills that are of vital importance to career and home business triumph.
Make Money Online While You Sleep
Make money business opporotunity: Are You Ready To Start Making money Online
Another alternative you can use to make money home business is to translate your skill set into a virtual environment. Anyone starting a home based business is usually a sole proprietor in that they are running a home business opportunity by themselves. All the facts state quite explicitly that IRS relief allowed to work at home is legally valid.
Home based business opportunity Parameter
* The Internet has various sources of information to help you develop effective business marketing practices.
* Being prepared to work alone can be a huge challenge for online business owners.
* Learn and implement offering hints
The advantages and disadvantages of operating a internet home based business in your home, especially the impacts on the family, are high-powered to explore as a first step in the process of deciding whether or not to start a work at home venture. Even if you are not a web-savvy tech guru, starting a website for your home business opportunity can still be relatively easy. Home based business ideas is one of the most frequently searched startup category with affiliate products.
When you know what you need, start looking for sources of capital. Inadequate capital is the cause of multiple work from home business failures even though most home-based businesses require a limited amount of start-up money. The internet makes it very, very easy and inexpensive for people to embark on a home based business these days.
Make Money Online Legitimately
Make money business opporotunity: Are You Tired Of Making payments From Day to day?
A bit of a downfall to having a home business is not having a shop front to promote the internet business. A home business is one of the most viable options to gain IRS relief. Anyone starting a home based business is usually a sole proprietor in that they are running a online business by themselves. If you're a procrastinator or if you have a low motivational level, a work from home is not for you.
Income earning Strategies
* Working as part of a team that nurtures your strengths and skills makes so much extra sense.
* Most home based business opportunity owners can streamline their operations when economic pressures affect their bottom line profits.
* Building a strong customer base is the only way to make money on the internet.
At a first look it seems like they're using what is called Working at home. There are masses of alternative guidelines that people can go about generating an income, including work from home business, selling ebooks, and even stock market investing. Whether you work at home already, are thinking about it, or your life circumstances now make working from home essential or possible, be sure to think these benefits through as you choose your employment options. When developing the sales campaign strategy you should consider the following:
The target market.
Most home-based businesses start out thanks to only one person in the affiliate marketing business. The average business opportunity requires about $10,000 in start-up costs whereas most Internet home based business opportunity start-up is usually under $3000.. There are several facets to consider when starting a work from home business.


text:
OXFORDSHIRE'S Lawrence Clarke went second in this year's UK 110m hurdles rankings after finishing third at the FBK Games.
The 24-year-old, from Christmas Common, recorded a season's best time of 13.41secs at yesterday's IAAF World Challenge meeting in Hengelo, Netherlands.
William Sharman, the UK No 1, took victory in 13.32, with China's Wenjun Xie second in 13.39.
Oxford City's Hannah England finished ninth in the women's 1,500m, also in a season's best time.
England recorded 4mins 5.27secs in a race won by home athlete Sifan Hassan (4.01.79) ahead of Britain's Laura Muir (4.02.91).
She tweeted: "Pretty pleased with a SB of 4.05 tonight, hopefully things will continue to get faster :) relieved to get the Euro champs standard too!"
With that performance, England rose to third in the 2014 UK rankings, behind Muir and Laura Weightman (4.02.72).
Meanwhile, England's Oxford City clubmate Nathan Douglas finished 11th and last in the triple jump at the Mohammed VI d'Athletisme in Marrakech.
Douglas's only legal leap of 14.96m was well his below his 2014 best of 16.65.
Latest Sport news


text:
share:Remind Me
powered by AFI
The viewed print was missing approximately thirteen minutes. According to Filmfacts, the missing footage included sequences in which "Tim Ochopee" initially befriends Stanley the rattlesnake by rescuing him from a predatory bird, and a scene in which Tim learns that "Dr. Everett" has betrayed him by selling snakes to "Richard Thomkins." In a March 1972 Hollywood Reporter interview, producer-director-writer William Gref relayed that he wrote the film's story after having a nightmare about snakes. After selling the idea to distributors Crown International, Gref then formed the Stanley Corporation with executive producer John H. Burrows to produce the picture.
Although a March 1972 Daily Variety news item reported that William Loos would write the film's score, only Post Production Associates is credited onscreen with the music score. The extent of Loos's contribution to the completed picture has not been determined. As noted in the onscreen credits, the film was shot entirely on location in the Everglades and at Ivan Tors Studios in Miami, FL. Another onscreen credit adds that animal sequences were filmed at Homosassa Springs, FL.
In a July 1972 letter to Los Angeles Times, Harvey M. Fischer, the assistant curator of reptiles at the Los Angeles Zoo, decried the film's apparent ill treatment of live snakes and its misleading representation of them as pets. In the March 1972 Hollywood Reporter article, Gref stated that fifteen live water moccasins, "with their mouths taped shut," were used in the sequence in which Tim fills Thomkins' swimming pool with snakes.


text:
"ISLAND TIME" - PRICED to SAIL!
This is a clean, well equipped and lightly used Beneteau 343. The 343 offers huge interior volume for her size and gives the feel of a larger boat. A very popular model, the 343 is equipped with roller furling main & genoa, Raymarine electronics, full canvas & custom interior cushions. This is a great opportunity on a lightly used Beneteau 343.
In our yard, Please call to schedule an appointment or with any questions you may have.
Please Contact:
Cameron Campbell 631-421-3400 office | 631-974-3099 mobile | firstname.lastname@example.com
The Beneteau 343 is a spacious vessel that offers more room than many larger vessels. With her huge aft cabin, large after head and spacious salon, she gives more than enough room for a family or long range cruising situation. The 343 is beautiful finished in a mahogany interior with all custom interior cushions.
Designed by Berret/Racoupeau, the Beneteau 343 is targeted to appeal to the discerning owner who wishes to find a finely finished yacht at an attractive investment level. Featuring more volume, a bigger interior, and better performance than it's predecessor the Beneteau 331. The 343 provides standard features that few sailboats of her size offer, including a separate stall shower.
17 Mill Dam Road
Huntington, Long Island, NY 11743
United States


text:
Emergent BioSolutions, Inc. (NYSE:EBS)
Q2 2012 Earnings Conference Call
August 2, 2012 05:00 PM ET
Daniel J. Abdun-Nabi - President and CEO
R. Don Elsey - SVP Finance & Administration, and CFO
Adam R. Havey - EVP and President, BioDefense Division
W. James Jackson, Ph.D - SVP and Chief Scientific Officer
Robert Burrows - VP of Investor Relations
Cory Kasimov - JP Morgan Chase & Co
Nicholas Bishop - Cowen and Company, LLC, Research Division
Mario Corso - Caris & Company
Matthew Miksic - Piper Jaffray & Co.
Good day ladies and gentlemen and welcome to the Emergent BioSolutions Second Quarter of 2012 Financial Results Conference Call. My name is Ian and I will be your operator for today. At this time, all participants are in a listen-only mode. We will conduct a question-and-answer session towards the end of this conference. (Operator Instructions) And as a reminder, this call is being recorded for replay purposes.
I'd now like to turn the call over to Bob Burrows, Vice President of Investor Relations. Please proceed, sir.
Robert Burrows
Thank you, Ian. Good afternoon, ladies and gentlemen. Thank you for joining us today as we discuss Emergent BioSolutions second quarter of 2012 financial results.
As is customary, our call today is open to all participants. In addition, the call is being recorded and it's copyrighted by Emergent BioSolutions. The call today will start with a brief prepared comments by our President and Chief Executive Officer, Dan Abdun-Nabi, who will give an overview of our financial performance for the second quarter, a brief business update and our 2012 forecast, including revenue expectations for the third quarter. Then, our CFO, Don Elsey will go through the financials in detail before we open up the call for your questions. We have several other members of senior management available to respond to your questions.
Before we begin, I'm compelled to remind everyone that during the call management may make projections and other forward-looking statements regarding future events and the Company's prospects for future performance. These forward-looking statements reflect Emergent's current perspective on existing trends and information. Any such forward-looking statements are not guarantees of future performance and involve substantial risks and uncertainties. Actual results may differ materially from those projected in any forward-looking statements. You are encouraged to review Emergent's filing with the SEC on forms 10-K, 10-Q and 8-K for more information on the risks and uncertainties that could cause actual results to differ.
For the benefit of those who may be listening to replay, this call is held and recorded on August 2, 2012. Since then, Emergent may have made announcements relating to topics discussed during today's call. So again, please reference our most recent press releases and SEC filings. Emergent BioSolutions assumes no obligation to update the information in today's press release or as presented on this call, except as may be required by applicable laws or regulations. Today's press release may be found on our website at www.emergentbiosolutions.com under investors/news.
And with that introduction, I'd now like to turn the call over to Dan Abdun-Nabi, Emergent BioSolutions, President and CEO. Dan?
Daniel J. Abdun-Nabi
Thank you, Bob. Good afternoon, everyone and thank you for joining our call today. In my prepared comments, I will review our results for the second quarter and year-to-date, discuss our achievements for this quarter, and highlight certain near-term milestones. I will conclude my remarks with our guidance for the third quarter and for the full-year.
To begin, our total revenues for the second quarter were just over $70 million. This is within the guidance that we provided during our May conference call. Year-to-date total revenues were approximately $121 million. Net income for the quarter was $7.6 million and was approximately $800,000 for the first six months of the year.
Turning to our achievements during the second quarter, we made progress on a number of initiatives. We commenced the manufacturing of consistency lots in Building 55. This represents a significant step towards licensure of this large scale BioThrax manufacturing facility. Once completed the consistency lot material will be used in our pivotal non-clinical study.
The data from that study together with other comparability data, will be reviewed by FDA as part of our licensure package. Last year FDA indicated its overall support for our plan for regulatory approval of Building 55 without the need for conducting clinical trials. This regulatory plan is based on achieving specified end points in our proposed comparability and non-clinical studies. More recently during the second quarter, FDA notified us that they concurred with the design of our pivotal non-clinical study. If we're successful in this plan, we remain confident that licensure could occur in late 2014.
As a remainder, we're receiving development funding from BARDA to support the licensure of Building 55 for the manufacturer of BioThrax. In terms of BioThrax improvements we accomplished two important milestones during the second quarter. First, FDA approved an amendment to our BioThrax generally used prophylaxis or GUP label. The BioThrax label not provide for a three-dose primary series with booster doses thereafter. This is an important milestone that was achieved with significant support by the U.S. government .We believe the achievement of this milestone addresses a key requirement and enhances the value of BioThrax to our principle customers within the U.S. government.
Second, we completed enrolment in the pivotal immunogenicity study of BioThrax for a post-exposure prophylaxis or PEP indication. This is being conducted under our current BARDA contract. We also secured an additional BARDA contract to support a Phase 2 non-interference study related to a PEP indication for BioThrax.
Regarding PreviThrax, a recombinant anthrax vaccine candidate, we recently reviewed our progress with representatives from BARDA. Based on that review we believe that BARDA will exercise an upcoming one-year option under the current development contract that we have with them. We expect to receive formal notice of this exercise in the third quarter of this year.
Lastly, HHS has awarded us a contract to establish a Center of Innovation in Advanced Development and Manufacturing. This contract will involve the use of both our Baltimore and Gaithersburg sites. Contracts were also awarded to Novartis, and Texas A&M, which is partnered with GlaxoSmithKline. These centers will address several HHS goals regarding public health emergencies including ensuring that the U.S. can quickly develop and manufacture medical counter measures, reducing U.S. dependents on vaccines made in other countries and developing the next generating of Americas biotechnology workforce.
Our contract consistent with an initial eight-year cost reimbursable, cost share base period of performance, with a fixed price component that would result in funding to us, up to a $163 million. The base contract period includes securing a pandemic influenza vaccine candidate, constructing additional facilities to support pandemic influenza vaccine production and obtaining facility licensure to manufacture a pandemic influenza vaccine at the Baltimore site.
The contract also contemplates up to 17 additional one-year options. Further BARDA may issue task orders for additional services including the manufacture and delivery of up to 50 million doses of influenza vaccine in the event of a pandemic and developing and manufacturing services to other companies developing counter measures against CBRN anthrax.
We're currently evaluating several potential flu vaccine candidate that meet HHS requirements and that could be manufactured in our Baltimore site. We expect to make our final selection in the near-term. This award represents a long-term public private partnership with BARDA to help achieve our common goal of strengthening the nations preparedness and response to pandemic.
Turning now to the second half of this year, we anticipate achieving the following key milestones in both our BioDefense and Bioscience divisions. In terms of our BioDefense programs, we expect to initiate the BioThrax PEP Phase 2 antibiotic noninterference study, in addition we expect to initiate a Phase 2 clinical study of NuThrax also for a PEP indication.
Regarding milestones for our Bioscience program, for TRU-016 in NHL, we will complete the Phase 1b comparative study and we will make a determination regarding going forward with the Phase 2 study for TRU-016 in CLL recruitment is ongoing and patient dosing continues in the Phase 2 combination study. The success of this Phase 2 combination study will determine whether a Phase 3 study is warranted. We anticipate making that determination in mid 2013.
For MVA85A, our tuberculosis vaccine candidate, we anticipate receiving the data from the 2,800 infant Phase 2b field efficacy study at the end of the year or shortly thereafter. As you may recall, MVA85A is a one dose booster to BCG. That's in Asian Phase of the trial, it has been completed and these entrants are now being observed.
Let me take a moment to discuss the public health red globally that should tuberculosis represents. Approximately 2 billion people or 1/3 of the worlds population are estimated to be infected with the bacteria and our risk of developing tuberculosis. According to the WHO approximately 1.5 million people die from TB every year worldwide. Tuberculosis is the second leading cause of death from infectious disease globally and according to the CDC is the leading cause of death among HIV infected individuals.
As I had mentioned in prior calls, the public health challenge has been intensified by the rise of TB strains that fail to respond to the most affected TB treatments. The global healthcare community is increasingly focused on the TB issue. In fact, in a press release issued in March of this year, the President of the Global Health Program at the Bill and Melinda Gates Foundation said, and I quote there is an urgent need for the global community to support the full range of tools to eliminate tuberculosis. But the development of TB vaccines that can prevent men, women, and children from developing the disease would be the single greatest events in the global fight against TB.
We're actively participating in a number of organizations worldwide involved in addressing the global health concern, collaborated with Aeras, The Wellcome Trust, SATVI, NIAID, Oxford University, EDCTP and other key opinion leaders all in pursuit of the solution to this substantial unmet global heath need. This collaborations have enabled us to conduct the field efficacy study as well as other clinical trials and to engage in other efforts in order to clarify a rapid path to licensure. We've also engaged in discussions with representatives of the WHO regarding MVA85A and our approach to the TB issue.
Given the heavy disease burden worldwide and the recognized need for a new TB vaccine, we may depending on the data from the ongoing study be in a position to pursue accelerated or conditional approval for MVA85A in selected countries. With respect to the market opportunities for MVA85A we've four commercial rights to approximately 55 high income and middle income countries, including in the EU, Russia and Brazil as well as in the private markets in both India and China.
Within our commercial market, there are an estimated 45 million to 50 million births annually. Even at a modest price per dose and assuming a one dose booster regimen, this represents a significant market opportunity for Emergent. So in summary, MVA85A offers a promise of addressing a significant global health threat, while representing a substantial commercial opportunity for Emergent.
Finally, let me conclude with our guidance. In the third quarter we're forecasting total revenues between $60 million to $70 million and the full-year we've reaffirm our guidance of total revenues between $280 million to $300 million and net income between $15 million to $25 million.
That concludes my prepared comments. And now I will turn it over to Don who will take you through the numbers in greater detail.?
R. Don Elsey
Thank you, Dan. Good afternoon, everyone. Following the close of the markets today, we released our financial results for the second quarter of 2012. I encourage everyone to take a look at the press release, which is currently available on our website. We plan to file our quarterly report on Form 10-Q with the SEC no later than the close of business tomorrow Friday August 3rd. The 10-Q will also be available on our website.
Let me now briefly discuss the numbers. Second quarter 2012 total revenues were $70.4 million versus $88.1 million in the second quarter of 2011. Total revenues for the first six months of 2012 were a $120.7 million versus a $106.7 million for the first half of 2011. Diving a little deeper, year-to-date product sales revenues were $87.5 million versus $77.1 million for the first six months of last year. This increase was driven by a 23% increase in the number of BioThrax doses delivered.
Year-to-date contracts and grants revenues were $33.2 million versus $29.6 million for the same period last year. This increase was primarily due to increased activity under our BARDA development contract for Building 55 and PreviThrax.
Turning to gross margins, our gross margin in Q2, 2012 was approximately 75%, which is within our typical range of between 70% and 80%. Gross margin for the first six months of 2012 was approximately 76%. Turning to the bottom line, second quarter 2012 net income was $7.6 million or $0.21 per basic share as compared to $14.2 million or $0.40 per basic share in the second quarter of 2011.
Net income for the first six months of 2012 was $800,000 or $0.02 per share as compared to a net loss of $7.2 million or a loss of $0.20 per share for the first half of 2011. Year-to-date net income reflects the impact of the $9.6 million non-cash charge in the first quarter. If you adjust for this non-cash charge, 2012 year-to-date net income were $7.8 million or $0.22 per share.
Turning now to spending. Our R&D expenses for the second quarter of 2012 were $30.6 million compared to $31.5 million in the same period last year. I'd like to highlight that contracts and grants revenues and costs associated with noncontrolling interest in our joint ventures offset a portion of our gross R&D expenses. When we take these into account, our net R&D for Q2 2012 was $11.3 million. R&D expenses for the first six months of 2012 were $56.9 million compared to $66.2 million in the first six months of 2011.
Again, adjusting for contracts and grants, revenues and noncontrolling interest in our joint ventures, the net R&D for the first half of 2012 was $20.4 million. Our SG&A expenses for the second quarter of 2012 were $17.9 million compared to $20.4 million in the second quarter of 2011. The decrease is primarily attributable to the restructuring charges related to our U.K. operations that we incurred in 2011. SG&A expenses for the first six months of 2012 were $37.4 million compared to $38.6 million for the first half of 2011.
Turning now to the balance sheet, we ended the second quarter of 2012 with cash and cash equivalents of $161.8 million and an accounts receivable balance of $46.8 million.
That concludes my comments. I will now turn the call over to the operator, so that we can begin the question-and-answer portion of the call. Operator, please proceed.
Question-and-Answer Session
Thank you. (Operator Instructions) Your first question comes from the line of Cory Kasimov of JP Morgan. Please proceed.
Cory Kasimov - JP Morgan Chase & Co
Hey, good afternoon guys and thanks for taking my questions. I have a few of them for you. First of all just wondering if the FDA approval of the new three dose primary series for BioThrax, if that has any impact on pricing going forward?
Daniel J. Abdun-Nabi
No, Cory. By the way, thanks for participating today. No, it doesn't have any impact on pricing under the contract.
Cory Kasimov - JP Morgan Chase & Co
Okay. And then, Don are you able to talk a little bit about the logistics of your planned buyback, is there any granularity or anything you can give us there?
R. Don Elsey
Yeah, I think in terms of timing and next steps, we as you know have Board approval, we've announced that. We now through the mechanisms that would be established under a formal plan and we expect that would be initiated sometime in the very near term.
Cory Kasimov - JP Morgan Chase & Co
Okay. And then lastly, and I missed part of what you had said on the pending TB data. So, I am sorry if you're repeating this; but do you have a sense of what your next steps are going to be if the Phase 2b results are positive at the end of this year?
R. Don Elsey
Yeah, I think what we've talked about and we've already had some preliminary discussions with some key opinion leaders and representatives in the public health community, an approach that might permit for either accelerated or conditional approval. And we do need to sit down with regulatory authorities and to find exactly how that will work. But big picture, the concept would be; we would be approved to manufacture and supply the product in select territories to start to begin to address the public health threat, while at the same time either undertaking follow-on Phase 3 study or some other level of activity that would support the data that we saw in the Phase 2b, and the exact parameters and what that might look like remains to be decided, but I think a lot is – as I said, a lot will be depending on what the data looks like.
Cory Kasimov - JP Morgan Chase & Co
Okay. So, something potentially along the lines of an accelerated approval for a cancer drug for example in the United States?
R. Don Elsey
I think that's a fair comparator. But again it's premature to give too much definition to it, but that's our concept exactly.
Cory Kasimov - JP Morgan Chase & Co
Okay. All right, great. Thank you very much. That's helpful.
Thank you for your question. The next question comes from the line of Nicholas Bishop of Cowen. Your line is live. Please proceed.
Nicholas Bishop - Cowen and Company, LLC, Research Division
Thanks. First just a couple of financial ones for Don. I wonder if you can give us any qualitative guidance on the contract and grants line over the next two quarters, I mean, I know you know what the annual guidance is, but you alluded to some potential new contracts in the third quarter. Is the third quarter likely to be higher than the fourth or is there any help you can give us there?
R. Don Elsey
Generally speaking as we take a look at the consolidation of contracts and grants and putting [Avium] aside for a moment. I would say that it's a fairly straight line over the next two quarters Nick well we don't breakout specific guidance on those, it of course depends on a variety of milestones that are being reached with various contracts and approval from various agencies to proceed with various steps. So it's always a little hard to tell even from within the company.
But I think relatively evenly divided over the next couple of quarters on contracts and grants putting [Avium] aside, let me just make a quick comment on the [Avium] as we talked about earlier when we announced [Avium] we don't anticipate it will have a material impact on 2012 and we anticipate that we will have the accounting for that scored away certainly in the latter part of this year and we'll explain that more fully as we come to conclusion with the SEC and we'll reflect that in our guidance for 2013 when we publish that in January of next year.
Nicholas Bishop - Cowen and Company, LLC, Research Division
Okay, great, that's helpful. And then on BioThrax, I guess based on your guidance and the pattern for last year it's reasonable to assume a pretty large fourth quarter on that; is that fair to say?
R. Don Elsey
That is correct, given our annual guidance reaffirmation and the Q3 guidance that we gave you its quick mathematical exercise and it will be a large fourth quarter.
Nicholas Bishop - Cowen and Company, LLC, Research Division
Okay. And then, just one last one; I wonder if you could on the Building 55 process, just remind us kind of the timing and kind of gating factors in completing the pivotal and comparability studies and what the design of those studies is?
Daniel J. Abdun-Nabi
Yeah, so let me start and then I would like to have Adam Havey the President of our BioDefense Division to add a little color. As we indicated really the plan that's been worked out with FDA is based on comparability and non-clinical programs, and we have reached agreement as to what those endpoints are to look like. So we're now initiating the process of conducting those studies and Adam can give you a little bit better clarity in terms of timeline and what the milestones going forward to BLA submission might look like.
Adam R. Havey
Yeah, thanks. At a high level as Dan mentioned we initiated our consistency lots which is the – kind of the first step in the process and we'll wrap those up in this quarter, that will then lead into the start of our pivotal non-clinical study, and that will run primarily through 2013. And then we'll prepare our FDA submissions, submit it to the FDA and go through the standard of regulatory approval process and hopefully with licensure late 2014.
Nicholas Bishop - Cowen and Company, LLC, Research Division
Okay, thanks. That's very helpful.
Thank you for the question. Next question comes from the line of Mario Corso of Caris & Company. Please proceed.
Mario Corso - Caris & Company
Yes, thank you for taking my question. So for the second quarter, your revenue numbers came in towards the low-end of your guidance. So as we think about the BioThrax I'm wondering what you can say about the quarter and going forward, kind of where you are on a yield basis, where you are on a shipment basis, did something there not occur as well as it could have in order to hit a better part or the upper part of your guidance. And then in terms of the Building 55 lots, I assume that will be – [on serially] so will you be getting some data soon and will that be shared with us or is it just continue on as planned. And then finally on NHL, can you talk a little bit more there about what the go, no-go decision is going to be based upon? Thanks a lot.
Daniel J. Abdun-Nabi
Sure. Let me start – thank you for the question. So, in terms of the revenue, if you look back to the first quarter for example we were at the very upper ends of our guidance and this quarter it was sort of at the low-end of the guidance. So, we do our best based on the production schedule and deliveries and to give a sense for where we're going to come out on the revenue basis, but it doesn't always work perfectly according to plan. But, I think we typically, historically have said, look at the whole user. But in an effort to give further visibility to you as you look at our company, we've broken this down on a quarterly basis. So, sometimes it will come in, in the high side, sometimes it will come in, in the low side, but I think historically we've been pretty good about hitting our range numbers. So, I wouldn't read anything into that. It's just normal variance in terms of output and delivery.
In terms of the Building 55 lots, I am not sure I understand the question. The consistency lots are going to be produced, we've initiated, that would then lead into the conduct of the studies that Adam has described. So, I don't think there's any interim data that you would see, you would run the studies and you collect the data and then you submit the package to FDA, big picture. So, it's not like there is an open-label study that's being conducted that would allow for an interim analysis that we could give you some guidance on over the course of that period. And I guess on the NHL, can you repeat the question, I didn't jot it down in time.
Mario Corso - Caris & Company
I just wanted to hear your thoughts about what the go; no-go decision is going to be based upon how you're looking at that at this point?
Daniel J. Abdun-Nabi
Yeah, so as we said we're waiting in completion of that, we'll look at the data and then make a specific determination. Jim Jackson, who is the Head of the Therapeutics on there and our CSO. Jim, you want to add a little color as to some of the metrics we all look at.
W. James Jackson, Ph.D
Sure, yeah. As Dan said we are in the process of analyzing the data from that 1b study. And as you know that was a study where we were looking at the additive effect of TRU-016 in combination with Bendamustine and Rituximab. It was a small study, only 12 subjects to it. We are probably looking somewhere around an improvement in the overall CR rate of about 30% over BR alone as kind of a threshold value for the additive effect of TRU-016. We are planning on getting this data together and presenting it later in the year probably at ASH, so that would be a time when we'll really kind of roll this information out publicly.
Thank you for the question. Our next question comes from the line of Ian Somaiya of Piper Jaffray. Your line is live. Please proceed.
Matthew Miksic - Piper Jaffray & Co.
Hi, good afternoon everyone, it's Matthew on for Ian. I just want to go back to the flu opportunity quickly. And I just was wondering if you could give a sense of maybe or an update on what your expectations are for – what we've been thinking about maybe just like a baseline volume for the flu contract. Obviously, total volume would be driven by the occurrence of a pandemic outbreak, but if you could maybe dimensionalize for us a little b4it what the baseline stock comp might look like and what the timing of that might be on an ongoing basis, that will be great. Thank you.
Daniel J. Abdun-Nabi
Yeah, thank you for your question, Matthew. So the [Avium] contract has a component to it that's not fixed in terms of delivery of up to 50 million doses and that's really not part of the base contract. Really what is contemplated now is that we would obtain licensure in a Baltimore site once we've selected the proper candidate and then I think it's going to be really up to the government to determine it. What its requirements are? Which products it would procure, at what levels? Clearly the government is looking for multiple suppliers, multiple product candidates and is investing in the development to get them across the goal line and obtain licensure.
But I think it's a little bit premature to be talking about specific contract procurements at this point. We hope as the program matures and develops, we'll have better clarity and we'll be able to pass that along to you with respect to vaccine stockpile amounts. But you know it is a priority from the government. They do have stockpiles in place today. They are developing additional candidates. They are now establishing these centers of innovation for advanced development and manufacturing. So, it remains a priority from the government and we're quite pleased that we're a part of it.
Matthew Miksic - Piper Jaffray & Co.
Okay, great. Fair enough. Thank you.
Thank you very much for your question. Just to let you know sir, at this time we have no further questions. (Operator Instructions) We have no further question's that has come through into the queue. I would now like to turn the call back over to Mr. Bob Borrows for closing remarks. Please proceed.
Robert Borrows
Thank you, Ian. In conclusion the Emergent's business is strong and growing as the premier provider of medical countermeasures against the anthrax with the U.S. Government. We continue to enhance the value and utility of BioThrax and to progress for a licensure of our large scale manufacturing facility. At the newly announced Center for Innovation in Advanced Development and Manufacturing we reported the long-term opportunity to help strengthen the Company's commitment, public health preparedness and the key participants in the fight against TB. We continue to work with our partners, collaborators and key stakeholders worldwide to advance our leading TB vaccines candidate MVA85A.
Ladies and gentlemen that's all the time we have today. Thank you for your participation. Please note that today's call has been recorded and a reply will be available beginning later today through August 16. Alternatively, there is available a webcast of today's call, an archived version of which will be available later today accessible through the Company's website. Thank you again and we look forward to speaking to all of you in the future. Goodbye.
Thank you, ladies and gentlemen for your participation in today's call. This concludes your presentation. You may now disconnect. Good day.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: email@example.com. Thank you!


text:
- Trending Now: More Trending:
- transgender beleaguer scaramouch non sequitur admiral's mast
Definition of toringin
: a crystalline flavone glucoside C21H20O9 that occurs in the bark of a shrubby Japanese crab apple (Malus sieboldii) and in the buds of several poplars and that yields chrysin and glucose on hydrolysis
There's more!
Love words? You must — there are over 200,000 words in our free online dictionary, but you are looking for one that's only in the Merriam-Webster Unabridged Dictionary.
Start your free trial today and get unlimited access to America's largest dictionary, with:
- More than 250,000 words that aren't in our free dictionary
- Expanded definitions, etymologies, and usage notes
- Advanced search features
- Ad free!
Origin and Etymology of toringin
New Latin toringo (specific epithet of Pyrus toringo, synonym of Malus sieboldii) (from Japanese, a crab apple tree) + English -in
Seen and Heard
What made you want to look up toringin? Please tell us where you read or heard it (including the quote, if possible).


text:
Sports car maker's belated entry to compact SUV market is practically perfect.
Homer Simpson once had a stab at building his version of the perfect car. The end result, unsurprisingly, was a dog's breakfast of awkward retro-styled angles and garish accessories.
Car companies, unlike deluded cartoon dad Homer, understand it's impossible to build one car to suit everyone, so they carefully assemble an entire range in the hope that one of their models will tick more of your boxes than their rival's.
Personally, my wish list for a car is one that's practical, with enough legroom and cargo space for when the family is on board. When they're not, it can go like a cut snake and corner as if on rails, all without shaking my fillings loose. It's also at all times comfortable, well appointed, and easy to park. A Porsche badge on the nose would be nice.
The German sports car maker's belated entry to the compact luxury SUV segment, dubbed the Macan, goes on sale this month and is already ticking a lot of Australian buyers' boxes. Six hundred so far, in fact, judging by deposits held by Porsche for its total 2014 allocation of 800 cars.
That's an impressive debut for a car that will set buyers back close to $100,000 once on-road costs are factored in. Looked at another way, though, the sticker price of $84,900 (before on-road costs are added) on the base diesel model also makes this easily the most affordable Porsche you can buy – for now. But more on that later.
Porsche forged its reputation for sporting performance on the racetracks of the world and backed it up with arguably the best and most enduring road-going sports car of all time, the classic 911.
With a pedigree like that you'd expect the Macan and its big brother, the large Cayenne SUV, to be well sorted, albeit in a lumbering sort of way. Porsche calls the new Macan "the sportscar among compact SUVs", and on the basis of a quick spin in all three models through the Great Ocean Road hinterland in south-western Victoria, it's hard to argue.
The range sweet spot is the $87,200 Macan S, with a petrol-powered 3.0-litre bi-turbo V6 making 250kW and 460Nm through the excellent seven-speed PDK dual-clutch auto. That's good enough to hustle to 100km/h in 5.4 seconds, quicker than a good many sports sedans.
If pace isn't your preference there's the Macan Diesel, which comes in $2300 cheaper than the S and with 190kW/580Nm has very different power delivery – still good enough to dispatch the ton in 6.3 seconds, though. The ace up its sleeve is fuel use, with its official 6.3L/100km significantly undercutting the S's 9.0L.
On the basis of these two rapid movers it's hard to make the case for stepping up to the $122,900 Macan Turbo, unless it's all about the badge on the back. Yes, 294kW and 550Nm and an official 9.2L/100km are sweet numbers, but does anyone really need an SUV that hits 100km/h in just 4.8 seconds?
It's your call, but with the performance on offer in the S model, we'd call the Macan Turbo a textbook case of diminishing returns.
In any guise the Macan sticks like glue to the damp, leaf-strewn roads on our drive route, the electric steering borrowed from the 911 inspiring confidence, if perhaps feeling a little heavy for comfortable manoeuvring in the urban grand prix of school runs and shopping trips.
Despite the fact our test cars ride on optional 20- and 21-inch rubber, there's almost no crashing and bashing in the cabin even on corrugated bitumen, and road noise abatement is astonishing. Regrettably, the same exceptional sound damping also completely masks the superb noise of those Porsche donks going about their business. Even flicking the chunky aluminium shift paddles back a few cogs on the entry to a corner to rev the engine above 5000rpm brings barely a murmur into the cabin.
Any wonder, then, that Porsche is bullish on this car's prospects across a wide range of demographics.
Porsche Cars Australia spokesman Paul Ellis says its order book is split between young buyers looking for performance with a touch of utility, and empty nesters seeking to reward themselves. Unlike most of the company's other models, the Macan also has strong appeal to women.
"The great thing about this car is that research has shown it's not gender-specific; our clinics show that as many women, compared to men, have the car really appeal to them," Ellis says.
He argues that sporting intent and practicality needn't be mutually exclusive. "Every car we build has to be the sportiest car in its segment. I will challenge anyone in the B-segment for the compact SUVs, to come close to this thing in terms of driving ability. Our point of difference is we're the sportiest. If it's not the sportiest, we don't sell it."
Is it the perfect car? You could pick on the lack of aural drama, but that also equates to greater serenity. You could argue the rear seat is a mite cosy for growing kids, but it's on par with other compact SUVs. You could say the steering's a tad too meaty for some, but the upside is fabulous feedback. Perfect? There's no such thing. But it's closer than a good many.
And if the entry price still looks a little steep, it may be prudent to bide your time. A more affordable four-cylinder version has been developed for Asian markets and while Ellis says it is "not on our radar at the moment", it is believed there is genuine interest in bringing the car here, ushering in a new era of affordability for the sought-after German.
The Macan isn't the first or last word in high-end family haulers that also have significant performance potential. Here are another five to consider:
Audi RS Q3
$81,900 plus on-road costs
The Macan S's most obvious rival is slightly cheaper, but also ceding 32kW/40Nm of stonk. It's also blighted by its "questionable value, unsporty driving position and weirdly unengaging cabin vibe", according to Drive.
Mercedes-Benz GLA 45 AMG
$79,900 plus on-road costs
The little Benz's huffed four makes 265kW and 450Nm and is significantly quicker on paper (0-100km/h in 4.8s) than the more expensive Macan S. Practical appeal is blunted, though, by the fact it's more of a high-riding hatch than an SUV.
BMW 328i Touring
$73,400 plus on-road costs
The 328i's turbocharged four is a cracker, responsive and decently frugal, and there's a respectable amount of space on offer relative to a nice cost saving over the similarly performance-focused SUVs here. The trade-off is the lack of a high driving position.
Audi RS6 Avant
$225,000 plus on-road costs
Probably the only road legal car on the planet that can hit 100km/h in a claimed 3.9 seconds while simultaneously carting your wardrobe or bed. It has plenty of family utility and a razor-sharp 4.0-litre V8 going for it. But you'll pay plenty.
Mercedes-Benz CLS 63 AMG Shooting Brake
$265,145 plus on-road costs
A long, wide load area marks the CLS Shooting Brake as a seriously practical yet head-turningly stylish option, while the brutal 5.5-litre twin-turbo V8 adds plenty of shove. Big car, big power, big head-turner, big price.


text:
David Richardson's argument that members of the Business Council of Australia represent narrow sectional interests and could therefore be ineligible for appointment to the Reserve Bank of Australia board ("RBA full of business heavies", January 7) is thin on several levels.
First, to suggest the focus of Australia's leading chief executives is "narrow" ignores large numbers of stakeholders, apart from shareholders, to whom they are increasingly accountable.
Richardson's contention also misrepresents the nature of the BCA, an organisation through which business leaders make a contribution to the development of national interest policy – in traditional areas like tax and regulatory reform but also in health, education and improving opportunities for indigenous Australians and for women.
And to say that the BCA includes many companies with "powerful positions in uncompetitive parts of the Australian industry" ("RBA board out of balance", Letters, January 7) fails to take account of the challenging global economy in which the vast majority of our members operate.
If the RBA board is to represent the Australian community, individuals who steer the nation's most successful businesses in a competitive world are well qualified to make a contribution.
Katie Lahey Chief executive Business Council of Australia Melbourne Vic, Letters